transcription	B:C1529556
factor	I:C1529556
activating	I:C1529556
enhancer	I:C1529556
-	I:C1529556
binding	I:C1529556
protein	I:C1529556
2C	I:C1529556
promotes	O
lung	B:C0024109
tumorigenesis	B:C0596263
and	O
aggressiveness	O
through	O
miR-183	B:C1101610
-	O
and	O
miR	B:C1101610
-33a	I:C1101610
-	O
mediated	O
cell	B:C1155872
cycle	I:C1155872
regulation	I:C1155872
.	O

Non	B:C0007131
-small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
Non	B:C0007131
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
remains	O
one	O
of	O
the	O
leading	O
causes	O
of	O
death	B:C0011065
worldwide	B:C2700280
,	O
and	O
thus	O
new	O
molecular	B:C1513403
targets	I:C1513403
need	O
to	O
be	O
identified	O
to	O
improve	O
treatment	O
efficacy	O
.	O

Although	O
epidermal	B:C0034802
growth	I:C0034802
factor	I:C0034802
receptor	I:C0034802
(	O
epidermal	B:C1414313
growth	I:C1414313
factor	I:C1414313
receptor	I:C1414313
)	O
/	O
KRAS	B:C1537502
mutation	B:C0596611
-	O
driven	O
lung	B:C0024109
tumorigenesis	B:C0596263
is	O
well	O
understood	O
,	O
the	O
mechanism	O
of	O
epidermal	B:C0034802
growth	I:C0034802
factor	I:C0034802
receptor	I:C0034802
/	O
KRAS	B:C0763464
-	O
independent	O
signal	O
activation	O
remains	O
elusive	O
.	O

Enhanced	B:C1529556
TFAP2C	I:C1529556
(	O
transcription	B:C1529556
factor	I:C1529556
activating	I:C1529556
enhancer	I:C1529556
-	I:C1529556
binding	I:C1529556
protein	I:C1529556
2C	I:C1529556
)	O
expression	B:C1171362
is	O
associated	O
with	O
poor	O
prognosis	B:C3854082
in	O
some	O
types	O
of	O
cancer	O
patients	O
,	O
but	O
little	O
is	O
known	O
of	O
its	O
relation	O
with	O
the	O
pathogenesis	B:C0699748
of	O
lung	B:C0684249
cancer	I:C0684249
.	O

In	O
the	O
present	O
study	B:C2603343
,	O
we	O
found	O
that	O
transcription	B:C1529556
factor	I:C1529556
activating	I:C1529556
enhancer	I:C1529556
-	I:C1529556
binding	I:C1529556
protein	I:C1529556
2C	I:C1529556
overexpression	B:C1514559
was	O
associated	O
with	O
cell	B:C0007613
cycle	I:C0007613
activation	I:C0007613
and	O
Non-	B:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
cell	B:C0007634
tumorigenesis	B:C0596263
.	O

Interestingly	O
,	O
transcription	B:C1529556
factor	I:C1529556
activating	I:C1529556
enhancer	I:C1529556
-	I:C1529556
binding	I:C1529556
protein	I:C1529556
2C	I:C1529556
blocked	O
AKAP12	B:C1454561
-	O
mediated	O
cyclin	B:C0174680
D1	I:C0174680
inhibition	O
by	O
inducing	O
the	O
overexpression	B:C0017262
of	O
oncogenic	B:C2825314
microRNA	I:C2825314
(	B:C1537817
miRNA	I:C1537817
)	I:C1537817
-	I:C1537817
183	I:C1537817
and	O
simultaneously	O
activated	O
cyclin-	B:C0252132
dependent	I:C0252132
kinase	I:C0252132
6	I:C0252132
-	O
mediated	O
cell	B:C1516334
cycle	I:C1516334
progression	I:C1516334
by	O
downregulating	B:C0013081
tumor	O
-	O
suppressive	O
miRNA	B:C1101610
-	I:C1101610
33a	I:C1101610
.	O

In	O
a	O
mouse	B:C2986594
xenograft	I:C2986594
model	I:C2986594
,	O
transcription	B:C3712863
factor	I:C3712863
activating	I:C3712863
enhancer	I:C3712863
-	I:C3712863
binding	I:C3712863
protein	I:C3712863
2C	I:C3712863
promoted	O
lung	B:C0024109
tumorigenesis	B:C0596263
and	O
disease	O
aggressiveness	O
via	O
the	O
miR-183	B:C1101610
and	O
miR	B:C1101610
-33a	I:C1101610
pathways	B:C0037080
.	O

The	O
study	B:C2603343
provides	O
a	O
mechanism	O
of	O
mitogenic	B:C3537152
and	O
oncogenic	B:C3537152
signaling	I:C3537152
via	O
two	O
functionally	O
opposed	O
miRNAs	O
and	O
suggests	O
that	O
transcription	B:C1529556
factor	I:C1529556
activating	I:C1529556
enhancer	I:C1529556
-	I:C1529556
binding	I:C1529556
protein	I:C1529556
2C	I:C1529556
-	O
induced	O
cell	B:C0007613
cycle	I:C0007613
hyperactivation	I:C0007613
contributes	O
to	O
lung	B:C0024109
tumorigenesis	B:C0596263
.	O

